학술논문
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Document Type
Article
Author
Source
The Lancet; July 2018, Vol. 392 Issue: 10143 p222-231, 10p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus.